Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 3/20 | 0.38 |
| ▸ | NPY1R | P25929 | 2/20 | 0.38 |
| ▸ | NPY4R | P50391 | 2/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | TFPI | P10646 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.35 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.34 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065724 | 0.91 | SIRT2 (0.36) | TFPIVIPR1IL23R | |
| SCHEMBL2193565 | 0.87 | NPY4R (0.42) | NPY5RNPY1RNPY4RBACE1 | |
| SCHEMBL6129058 | 0.82 | KISS1R (0.38) | NPY5RNPY1RNPY4RTFPIIL23R | |
| SCHEMBL3215006 | 0.82 | MAPK8 (0.38) | HASPINVIPR2VIPR1IL23R | |
| SCHEMBL4099729 | 0.81 | NPY4R (0.32) | NPY5RNPY1RNPY4R | |
| SCHEMBL4100278 | 0.80 | NPY4R (0.46) | NPY5RNPY1RNPY4R | |
| SCHEMBL1351715 | 0.79 | NPY4R (0.43) | NPY5RNPY1RNPY4RTFPIRXFP1 | |
| SCHEMBL31031560 | 0.79 | TFPI (0.49) | NPY5RNPY1RNPY4RTFPIVIPR1 | |
| SCHEMBL2191238 | 0.79 | BACE1 (0.47) | NPY5RNPY1RNPY4RBACE1CTSD | |
| SCHEMBL6118576 | 0.79 | BACE1 (0.47) | NPY5RNPY1RNPY4RBACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | NPY5R 3577/4885NPY1R 3329/4885NPY4R 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.